Presentation is loading. Please wait.

Presentation is loading. Please wait.

Miles D et al. Proc SABCS 2012;Abstract P

Similar presentations

Presentation on theme: "Miles D et al. Proc SABCS 2012;Abstract P"— Presentation transcript:

1 Miles D et al. Proc SABCS 2012;Abstract P5-18-01.
Pertuzumab in Combination with Trastuzumab and Docetaxel in Elderly Patients with HER2-Positive Metastatic Breast Cancer in the CLEOPATRA Study Miles D et al. Proc SABCS 2012;Abstract P

2 Background Patients aged ≥65 years are underrepresented in trials of cancer treatments, thus limiting the availability of efficacy and safety data for new therapies in this population. The results from the Phase III CLEOPATRA trial evaluating the addition of pertuzumab versus placebo to trastuzumab/docetaxel for patients with HER2-positive metastatic breast cancer (mBC) (NEJM 2012;366:109): Demonstrated a significant improvement in PFS with pertuzumab by independent review. Led to the FDA approval of pertuzumab/trastuzumab/docetaxel as first-line therapy for HER2-positive mBC. Study objective: To compare the efficacy and safety of pertuzumab/trastuzumab/docetaxel according to age group for patients in the CLEOPATRA trial (<65 versus ≥65 years). Miles D et al. Proc SABCS 2012;Abstract P

3 CLEOPATRA Study Design
Centrally confirmed HER2- positive locally recurrent, unresectable or metastatic BC (mBC) ≤1 hormonal regimen for mBC Prior (neo)adjuvant systemic Rx including trastuzumab allowed if followed by DFS ≥12 mo Baseline LVEF ≥50%; no CHF or LVEF <50% during or after prior trastuzumab Docetaxel (≥6 cycles recommended) N = 406 Trastuzumab Placebo R 1:1 Docetaxel (≥6 cycles recommended) Trastuzumab N = 402 Pertuzumab Primary endpoint: Independently assessed progression-free survival (PFS) Miles D et al. Proc SABCS 2012;Abstract P

4 Independently Assessed PFS (ITT Population)
<65 years ≥65 years PL/T/D (n = 339) Pert/T/D (n = 342) PL/T/D (n = 67) Pert/T/D (n = 60) Median PFS 12.5 mo 17.2 mo 10.4 mo 21.6 mo Hazard ratio 0.65 0.52 95% CI p-value <0.0001 0.0098 PL = placebo; Pert = pertuzumab; T = trastuzumab; D = docetaxel Miles D et al. Proc SABCS 2012;Abstract P

5 Exposure to Docetaxel Treatment
<65 years ≥65 years PL/T/D (n = 332) Pert/T/D (n = 346) (n = 65) (n = 61) Median no. of cycles administered (range) 8.0 (1-41) 8.0 (1-35) 6.5 (1-26) 6.0 (1-16) Median dose intensity, mg/m2/week 24.8 24.5 Dose escalation, n (%)* 53 (16.0) 41 (11.8) 8 (12.3) 7 (11.5) Dose reduction, n (%)† 72 (21.7) 85 (24.6) 17 (26.2) 19 (31.1) * Dose escalation to 100 mg/m2; † Dose reduction to <75 mg/m2 Miles D et al. Proc SABCS 2012;Abstract P

6 Most Common Adverse Events: Overall (O) and After (A) Docetaxel Discontinuation
All grades (O/A, %) <65 years ≥65 years PL/T/D Pert/T/D Diarrhea 44.9/8.4 66.2/16.5 53.8/12.5 70.5/32.7 Neutropenia 51.2/3.7 54.3/2.0 41.5/2.5 44.3/0 Fatigue 36.1/7.9 36.1/10.0 40.0/12.5 45.9/16.3 Rash 22.9/6.0 34.7/10.8 30.8/7.5 27.9/16.3 Asthenia 29.2/7.9 25.7/10.8 35.4/7.5 27.9/4.1 Dysgeusia 14.8/0.9 16.8/0.8 20.0/0 Febrile neutropenia 7.8/0 14.7/0 6.2/0 8.2/0 Overall, the proportion of patients ≥65 y receiving G-CSF was lower than that of patients <65 y. Miles D et al. Proc SABCS 2012;Abstract P

7 Most Common Adverse Events (≥Grade 3)
<65 years ≥65 years PL/T/D (n = 332) Pert/T/D (n = 346) (n = 65) (n = 61) Neutropenia 47.0% 50.3% 40.0% 41.0% Leukopenia 15.4% 12.7% 10.8% 9.8% Febrile neutropenia 7.8% 14.7% 6.2% 8.2% Diarrhea 4.8% 6.6% 14.8% Fatigue 2.7% 2.0% 3.3% Peripheral neuropathy 1.8% 1.7% 1.5% LVSD 2.4% 1.2% 4.6% 1.6% Asthenia 2.9% 3.1% 0% Miles D et al. Proc SABCS 2012;Abstract P

8 Author Conclusions Treatment with Pert/T/D demonstrated a superior PFS by independent review in patients aged <65 years and ≥65 years compared with PL/T/D. In patients aged ≥65 years versus <65 years: There were more dose reductions of docetaxel. There was a lower median number of docetaxel cycles, which likely explains the lower incidence of neutropenia and febrile neutropenia and the less frequent use of G-CSF. The safety and efficacy data reported in the CLEOPATRA trial suggest that in patients with good ECOG PS, the combined use of Pert/T/D should not be limited by patient age. The PERUSE study will investigate the tolerability and efficacy of first-line Pert/T with one of a choice of taxanes in patients with HER2-positive mBC (NCT ). Miles D et al. Proc SABCS 2012;Abstract P

9 Investigator Commentary: Pertuzumab/Trastuzumab/Docetaxel for Elderly Patients with HER2-Positive mBC The results of the subset analysis of the CLEOPATRA trial based on age demonstrated that patients benefit from combination therapy with pertuzumab, trastuzumab and docetaxel irrespective of age. These results are consistent with what was found with anti-HER2 therapy in the adjuvant setting. It is a reminder that breast cancer should be managed based on the biology of the disease and the patient’s overall condition rather than age. Interview with Edith A Perez, MD, January 17, 2013 Anytime I see a survival advantage in any population of patients facing incurable metastatic breast cancer, I feel as if we’re making some progress in this area. To see the survival data from CLEOPATRA was exciting, and it was nice to see that the elderly population from CLEOPATRA not only derived a benefit but seemed to tolerate treatment well. No large outstanding safety signal was apparent. They required more dose reductions, but in general there were no more treatment-related deaths, and the responses appeared to be similar across the age groups. Interview with Kimberly L Blackwell, MD, January 8, 2013

Download ppt "Miles D et al. Proc SABCS 2012;Abstract P"

Similar presentations

Ads by Google